Get the Stockscreener App
1.60
1.27%
0.02
Quince Therapeutics Inc stock is traded at $1.60, with a volume of 132.72K.
It is up +1.27% in the last 24 hours and down -12.57% over the past month.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
See More
Previous Close:
$1.58
Open:
$1.58
24h Volume:
132.72K
Relative Volume:
0.63
Market Cap:
$85.94M
Revenue:
-
Net Income/Loss:
$-31.39M
P/E Ratio:
-1.9048
EPS:
-0.84
Net Cash Flow:
$-18.45M
1W Performance:
-0.62%
1M Performance:
-12.57%
6M Performance:
+7.38%
1Y Performance:
+117.69%
1-Day Range:
$1.58
$1.62
1-Week Range:
$1.56
$1.67
52-Week Range:
$0.69
$2.45
Quince Therapeutics Inc Stock (QNCX) Company Profile
Name
Quince Therapeutics Inc
Sector
Industry
Phone
415-910-5717
Address
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Compare QNCX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNCX
Quince Therapeutics Inc
|
1.60 | 86.48M | 0 | -31.39M | -18.45M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Quince Therapeutics Inc Stock (QNCX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-05-25 | Initiated | Citizens JMP | Mkt Outperform |
| Mar-24-25 | Initiated | Oppenheimer | Outperform |
Quince Therapeutics Inc Stock (QNCX) Latest News
Volume spikes in Quince Therapeutics Inc. stock – what they mean2025 Analyst Calls & Weekly High Momentum Picks - Newser
Chart based analysis of Quince Therapeutics Inc. trendsJuly 2025 Closing Moves & High Yield Stock Recommendations - Newser
How institutional ownership impacts Quince Therapeutics Inc. stockPortfolio Return Report & Low Risk High Win Rate Picks - Newser
Published on: 2025-09-12 20:44:55 - Newser
Is a relief rally coming for Quince Therapeutics Inc. holders2025 Technical Overview & Expert Verified Stock Movement Alerts - Newser
Will Quince Therapeutics Inc. stock recover after recent drop2025 Support & Resistance & Intraday High Probability Setup Alerts - Newser
Applying big data sentiment scoring on Quince Therapeutics IncDividend Hike & Daily Chart Pattern Signal Reports - Newser
Applying big data sentiment scoring on Quince Therapeutics Inc.Analyst Upgrade & Reliable Intraday Trade Alerts - Newser
Smart tools for monitoring Quince Therapeutics Inc.’s price actionJuly 2025 Pullbacks & Weekly High Conviction Trade Ideas - Newser
Quince Therapeutics Inc. stock trendline breakdown2025 Short Interest & Growth Oriented Trading Recommendations - Newser
Chart based exit strategy for Quince Therapeutics Inc.Portfolio Update Report & High Yield Stock Recommendations - Newser
Heatmap analysis for Quince Therapeutics Inc. and competitorsCPI Data & AI Based Buy/Sell Signal Reports - Newser
Quince Therapeutics Inc.’s volatility index tracking explained2025 Technical Patterns & Real-Time Volume Analysis Alerts - Newser
How to manage a losing position in Quince Therapeutics Inc.Earnings Trend Report & Daily Profit Maximizing Tips - Newser
Published on: 2025-09-12 05:17:11 - Newser
Is Quince Therapeutics Inc. stock poised for growthPortfolio Growth Summary & Daily Growth Stock Tips - Newser
Regression analysis insights on Quince Therapeutics Inc. performanceJuly 2025 WrapUp & Daily Entry Point Trade Alerts - Newser
Multi asset correlation models including Quince Therapeutics Inc.July 2025 Gainers & Community Supported Trade Ideas - Newser
Brokerages Set Quince Therapeutics, Inc. (NASDAQ:QNCX) Price Target at $8.14 - Defense World
Technical analysis overview for Quince Therapeutics Inc. stockJuly 2025 Short Interest & Accurate Buy Signal Alerts - Newser
Identifying reversal signals in Quince Therapeutics Inc.Layoff News & Risk Controlled Stock Pick Alerts - Newser
Ranking Quince Therapeutics Inc. among high performing stocks via toolsQuarterly Performance Summary & High Accuracy Swing Entry Alerts - Newser
Candlestick signals on Quince Therapeutics Inc. stock todayGap Down & Advanced Swing Trade Entry Alerts - Newser
Quince Therapeutics to Host Virtual Investor Day on October 2, 2025 - Business Wire
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Is Quince Therapeutics Inc. building a consolidation baseTrade Entry Summary & Weekly Watchlist of Top Performers - Newser
Published on: 2025-09-11 01:39:12 - Newser
Using data filters to optimize entry into Quince Therapeutics Inc2025 Market Trends & High Accuracy Swing Entry Alerts - Newser
is quince therapeutics inc. building a consolidation baseWeekly Loss Report & Weekly Breakout Stock Alerts - Newser
Historical volatility pattern of Quince Therapeutics Inc. visualizedJuly 2025 Macro Moves & Real-Time Buy Zone Alerts - Newser
Should you hold or exit Quince Therapeutics Inc. now2025 Big Picture & Community Trade Idea Sharing Platform - Newser
How to interpret RSI for Quince Therapeutics Inc. stockMarket Activity Summary & Free Daily Entry Point Trade Alerts - Newser
Custom strategy builders for tracking Quince Therapeutics Inc.Sell Signal & AI Enhanced Trade Execution Alerts - Newser
Quince Therapeutics Inc Stock (QNCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):